Obtenga las últimas noticias sobre las acciones de Cogent Biosciences con actualizaciones sobre las tendencias del mercado, las finanzas y el análisis de Benzinga. Manténgase informado sobre el rendimiento de COGT

Últimas noticias sobre

COGENT BIOSCIENCES INC

Cogent Biosciences

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Cogent Biosciences Inc

News

Press Releases

Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting

Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders

Earnings

Cogent Biosciences Reports First Quarter 2025 Financial Results

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference

Financing

Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing

Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis

Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock

Markets

Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Cogent Biosciences Reports Recent Business Highlights and  Second Quarter 2025 Financial Results

COGT

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Ardelyx

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals

BioCryst Pharmaceuticals, Inc. - Common Stock

BioCryst Pharma

Beam Therapeutics

Biohaven

Cidara Therapeutics

Celcuity

CG Oncology

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Dyne Therapeutics

Immunocore Holdings plc - American Depositary Shares

Immunocore Holdings

Disc Medicine

Janux Therapeutics

Mesoblast Limited - American Depositary Shares

Mesoblast

NuCana

Novavax

ARS Pharmaceuticals

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Vera Therapeutics, Inc. - Class A Common Stock

Vera Therapeutics

Viridian Therapeutics, Inc. - Common Stock

Comments

Cogent Biosciences Noticias bursátiles

Noticias

Últimas noticias sobre

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL